0.3100USD-6.91%Mkt Cap: 37.46M USDP/E: —Last update: 2026-05-22
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an o…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap37.46M USD
Enterprise Value47.16M USD
Revenue (TTM)205.70K USD
Gross Profit57.20K USD
Net Income (TTM)-62.42M USD
Revenue/Share0.0050 USD
Last Price0.3100 USD
Fiscal Year EndSep 2025
MR QuarterDec 2025
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.25
PEG—
EV/EBITDA-0.80
EV/Revenue229.28
P/S195.66
P/B-0.56
EPS (TTM)-1.13
EPS (Forward)-0.27
52W Range
0.16105% of range3.390
52W High3.390 USD
52W Low0.1610 USD
Profitability
Gross Margin4.05%
Oper. Margin1116.38%
EBITDA Margin0.00%
Profit Margin-4416.22%
ROE193.94%
ROA-335.90%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.83M USD
CapEx (TTM)—
FCF Margin-16732.43%
FCF Yield-91.89%
Net Debt28.22M USD
Net Debt/EBITDA-0.48
Balance Sheet
Debt/Equity-0.94
Current Ratio0.35
Quick Ratio0.18
Book Value/Sh-0.5970 USD
Cash/Share0.1040 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 18, 2019
Splits
Last Split1:20
Split DateMar 14, 2024
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)4.167 USD
Target Range0.5000 USD – 6.000 USD
# Analysts3
Ownership
Shares Out.120.86M
Float70.89M
Insiders15.52%
Institutions7.87%
Short Interest
Short Ratio1.3d
Short % Float5.33%
Short % Out.5.33%
Shares Short6.43M
Short (prev mo.)3.18M
Technical
SMA 500.2678 (+15.8%)
SMA 2000.9898 (-68.7%)
Beta0.33
S&P 52W Chg28.31%
Avg Vol (30d)5.15M
Avg Vol (10d)4.89M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—